|
1
|
Winder T and Lenz HJ: Vascular endothelial
growth factor and epidermal growth factor signaling pathways as
therapeutic targets for colorectal cancer. Gastroenterology.
138:2163–2176. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Van Cutsem E, Köhne CH, Hitre E, Zaluski
J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G,
et al: Cetuximab and chemotherapy as initial treatment for
metastatic colorectal cancer. N Engl J Med. 360:1408–1417. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jonker DJ, O'Callaghan CJ, Karapetis CS,
Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, et
al: Cetuximab for the treatment of colorectal cancer. N Engl J Med.
357:2040–2048. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Douillard JY, Oliner KS, Siena S,
Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham
D, Jassem J, et al: Panitumumab-FOLFOX4 treatment and RAS mutations
in colorectal cancer. N Engl J Med. 369:1023–1034. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,
Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil and
leucovorin for metastatic colorectal cancer. N Engl J Med.
350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Giantonio BJ, Catalano PJ, Meropol NJ,
O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA and Benson AB III:
Eastern Cooperative Oncology Group Study E3200: Bevacizumab in
combination with oxaliplatin, fluorouracil and leucovorin (FOLFOX4)
for previously treated metastatic colorectal cancer: Results from
the eastern cooperative oncology group study E3200. J Clin Oncol.
25:1539–1544. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Heinemann V, von Weikersthal LF, Decker T,
Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller
C, Kahl C, Seipelt G, et al: FOLFIRI plus cetuximab versus FOLFIRI
plus bevacizumab as first-line treatment for patients with
metastatic colorectal cancer (FIRE-3): A randomised, open-label,
phase 3 trial. Lancet Oncol. 15:1065–1075. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Venook AP, Niedzwiecki D, Lenz HJ,
Innocenti F, Mahoney MR, O'Neil BH, Shaw JE, Polite BN, Hochster
HS, Atkins JN, et al: CALGB/SWOG 80405: Phase III trial of
irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin
(mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients
(pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma
of the colon or rectum (MCRC). J Clin Oncol. 32:abstract LBA3.
2014.
|
|
9
|
Van Cutsem E, Cervantes A, Nordlinger B
and Arnold D: ESMO, Guidelines Working Group: Metastatic colorectal
cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment
and follow-up. Ann Oncol. (25 Suppl 3): iii1–iii9. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bennouna J, Sastre J, Arnold D, Österlund
P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C,
et al: Continuation of bevacizumab after first progression in
metastatic colorectal cancer (ML18147): A randomised phase 3 trial.
Lancet Oncol. 14:29–37. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Van Cutsem E, Tabernero J, Lakomy R,
Prenen H, Prausová J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko
V, Ferry D, et al: Addition of aflibercept to fluorouracil,
leucovorin, and irinotecan improves survival in a phase III
randomized trial in patients with metastatic colorectal cancer
previously treated with an oxaliplatin-based regimen. J Clin Oncol.
30:3499–3506. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Primrose J, Falk S, Finch-Jones M, Valle
J, O'Reilly D, Siriwardena A, Hornbuckle J, Peterson M, Rees M,
Iveson T, et al: Systemic chemotherapy with or without cetuximab in
patients with resectable colorectal liver metastasis: The New EPOC
randomised controlled trial. Lancet Oncol. 15:601–611. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Madi A, Fisher D, Wilson RH, Adams RA,
Meade AM, Kenny SL, Nichols LL, Seymour MT, Wasan H, Kaplan R, et
al: Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in
advanced colorectal cancer: The MRC COIN trial. Br J Cancer.
107:1037–1043. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cunningham D, Humblet Y, Siena S, Khayat
D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype
C, et al: Cetuximab monotherapy and cetuximab plus irinotecan in
irinotecan-refractory metastatic colorectal cancer. N Engl J Med.
351:337–345. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lacouture ME, Mitchell EP, Piperdi B,
Pillai MV, Shearer H, Iannotti N, Xu F and Yassine M: Skin toxicity
evaluation protocol with panitumumab (STEPP), a phase II,
open-label, randomized trial evaluating the impact of a pre-Emptive
Skin treatment regimen on skin toxicities and quality of life in
patients with metastatic colorectal cancer. J Clin Oncol.
28:1351–1357. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
James K, Eisenhauer E, Christian M,
Terenziani M, Vena D, Mudal A and Therasse P: Measuring response in
solid tumors: Unidimensional versus bidimensional measurement. J
Natl Cancer Inst. 91:523–528. 1991. View Article : Google Scholar
|
|
17
|
Common Terminology Criteria for Adverse
Events v3.0 (CTCAE). 2006.http://www.jcog.jp/doctor/tool/CTCAEv3J_070308.pdfAccessed.
March 08–2007
|
|
18
|
Van Cutsem E, Peeters M, Siena S, Humblet
Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J,
Richardson G, et al: Open-label phase III trial of panitumumab plus
best supportive care compared with best supportive care alone in
patients with chemotherapy-refractory metastatic colorectal cancer.
J Clin Oncol. 25:1658–1664. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Doi T, Ohtsu A, Tahara M, Tamura T, Shirao
K, Yamada Y, Otani S, Yang BB, Ohkura M and Ohtsu T: Safety and
pharmacokinetics of panitumumab in Japanese patients with advanced
solid tumors. Int J Clin Oncol. 14:307–314. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
André T, Blons H, Mabro M, Chibaudel B,
Bachet JB, Tournigand C, Bennamoun M, Artru P, Nguyen S, Ebenezer
C, et al: Panitumumab combined with irinotecan for patients with
KRAS wild-type metastatic colorectal cancer refractory to standard
chemotherapy: A GERCOR efficacy, tolerance and translational
molecular study. Ann Oncol. 24:412–419. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hasegawa H, Yoshida M, Taira K, Sugimoto
N, Kii T, Takeda K, Yoshinami T, Sakai D, Satou T, et al: A Phase
II study of pmab + IRI FOR mCRC PTS with WildKRAS, resistant to
fluoropyrimidine, oxaliplatin and IRI (OGSG1001). Ann Oncol.
25(Suppl 5): v44–v74. 2014.
|
|
22
|
Peeters M, Price TJ, Cervantes A, Sobrero
AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, et al:
Randomized phase III study of panitumumab with fluorouracil,
leucovorin and irinotecan (FOLFIRI) compared with FOLFIRI alone as
second-line treatment in patients with metastatic colorectal
cancer. J Clin Oncol. 28:4706–4713. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Seymour MT, Brown SR, Middleton G, Maughan
T, Richman S, Gwyther S, Lowe C, Seligmann JF, Wadsley J, Maisey N,
et al: Panitumumab and irinotecan versus irinotecan alone for
patients with KRAS wild-type, fluorouracil-resistant advanced
colorectal cancer (PICCOLO): A prospectively stratified randomised
trial. Lancet Oncol. 14:749–759. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sobrero AF, Maurel J, Fehrenbacher L,
Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C,
Steinhauer EU, Prausova J, et al: EPIC: Phase III trial of
cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin
failure in patients with metastatic colorectal cancer. J Clin
Oncol. 26:2311–2319. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kobayashi Y, Komatsu Y, Yuki S, Fukushima
H, Sasaki T, Iwanaga I, Uebayashi M, Okuda H, Kusumi T, Miyagishima
T, et al: Randomized controlled trial on the skin toxicity of
panitumumab in Japanese patients with metastatic colorectal cancer:
HGCSG1001 study; J-STEPP. Future Oncol. 11:617–627. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schimanski CC, Moehler M, Zimmermann T,
Wörns MA, Steinbach A, Baum M and Galle PR: Cetuximab-induced skin
exanthema: Improvement by a reactive skin therapy. Mol Med Rep.
3:789–793. 2010.PubMed/NCBI
|
